1. Vocabria Pills Were Used First to See How Well People Handled the Drug
Vocabria is a pill. It's approved to be taken for a short time before someone starts Cabenuva shots to treat HIV or Apretude shots to help prevent HIV (also called HIV PrEP). It can also be used for a short time if someone can't get their Cabenuva or Apretude shot on schedule.
Several studies tested this approach. The FLAIR, ATLAS, and ATLAS-2M studies looked at adults. The IMPAACT2017/MOCHA study looked at teens. In these studies, people took Vocabria pills before starting Cabenuva shots. Two other studies, called HPTN 083 and HPTN 084, had people take Vocabria pills before starting Apretude shots to help prevent HIV.
Starting Cabenuva shots right away, without taking pills first, is also an approved option. This was studied as part of the FLAIR trial. Your doctor can help you decide which approach makes sense for you.
2. Who Took Part in These Studies?
The studies included adults and teens who were being treated for HIV. They also included adults who wanted to help prevent HIV. Everyone in the studies took Vocabria pills first, then switched to long-acting shots.
3. Starting With Pills Worked About as Well as Starting With Shots Right Away
The FLAIR study followed people for a longer period of time. Some people took Vocabria pills before starting Cabenuva shots. Others started Cabenuva shots right away, with no pills first. Both groups did well.
After about two and a half years (124 weeks), 93 out of 100 people who took pills first still had their HIV under control. Among people who started with shots right away, 99 out of 100 people had their HIV under control. "Under control" means a very low level of HIV in the blood.
This comparison comes from a later phase of the study where people were not randomly assigned to a group, so it isn't a formal head-to-head comparison. Researchers considered the difference between the two groups to be small.
4. Most People Took the Pills for About a Month
In the studies for HIV treatment (FLAIR, ATLAS, and ATLAS-2M), people took Vocabria pills for four weeks before starting Cabenuva shots. In the studies for HIV prevention (HPTN 083 and HPTN 084), people took Vocabria pills for five weeks before starting Apretude shots.
5. Side Effects Were About the Same Either Way
In the longer FLAIR study, side effects were similar for both groups. By around two and a half years, 92 out of 100 people who started with shots right away had at least one side effect. Among people who took pills first, 83 out of 100 had at least one side effect.
Most side effects were mild. But some serious side effects need quick medical attention, including severe rash or allergic reaction, liver problems, and mood changes or depression. This is not a full list.
The Bottom Line
An oral lead-in is one option for starting HIV treatment or prevention — but not something everyone has to do. Talk to your doctor about whether taking Vocabria pills first is a good fit for you, or whether starting injections right away makes more sense for your situation.
